Immunotherapy of hepatocellular carcinoma

Published on June 29, 2023   36 min

Other Talks in the Series: Immunotherapy of Cancer

Please wait while the transcript is being prepared...
Hello, my name is Tim F. Greten and I'm a senior investigator in the United States and I'm going to talk about immunotherapy of hepatocellular carcinoma. I have received my training back in Germany and I've been working in this field for many years and it's truly an exciting topic and I'm excited to give this presentation to you. So let's get started. The topic
has really gained a lot of interest recently. If you put into PubMed just the two terms, hepatocellular and immune, you can see the number of hits in PubMed over time, basically demonstrating the relevance and the significance of this topic. In addition, there is a great financial interest. It is expected the unresectable HCC market was valued at approximately USD 1,487.75 million in 2021. By 2027, we expect this number to go even further up to USD 2,851 million. So let's get started with the science.
HCC and biliary tumors, which are both primary liver cancers, are actually pretty common worldwide as well as in the United States. In the United States, it is actually the number five in terms of cancer-related deaths in men and the number seven in women.
A big problem is that the 10-year mortality trend has not really changed in the past years for liver and intrahepatic bile duct cancer, indicating the big need to advance new treatments.